Advertisement

Cardiometabolic Disorders in Psoriatic Disease

  • Curtis Sobchak
  • Lihi Eder
Psoriatic Arthritis (J Scher, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Psoriatic Arthritis

Abstract

Purpose of Review

Patients with psoriasis and psoriatic arthritis, collectively termed psoriatic disease (PsD), are at an increased risk of developing cardiovascular diseases (CVD). The purpose if this manuscript is to review recent evidence about the epidemiology and underlying mechanisms of CVD in psoriatic patients and approaches to improve the management of these comorbidities.

Recent Findings

Studies have shown that CVD risk is independent of traditional cardiovascular risk factors and is related to the systemic inflammatory nature of PsD. The use of surrogate markers, such as imaging of subclinical atherosclerosis, allows detection of patients at high cardiovascular risk before the occurrence of clinical events. These modalities could be clinically useful as clinical cardiovascular risk algorithms, such as the Framingham Risk Score, and have been shown to underestimate the actual cardiovascular risk in patients with PsD. Additional challenges related to the management of CVD in psoriatic patients include the underdiagnosis and undertreatment of traditional cardiovascular risk factors in rheumatology, dermatology and primary care setting. Effective measures used to control PsD, such as tumour necrosis factor inhibitors and methotrexate, has been associated with reduced cardiovascular risk in psoriatic patients.

Summary

These findings highlight the importance of controlling disease activity as potential target that could lead to reduced cardiovascular risk. Together this highlights the importance of optimization of cardiovascular risk stratification and management of cardiovascular risk factors in patients with PsD.

Keywords

Psoriatic arthritis Psoriasis Atherosclerosis Cardiovascular disease Inflammation 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537–41.CrossRefPubMedGoogle Scholar
  2. 2.
    Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2:ii):14–7.Google Scholar
  3. 3.
    Ahlehoff O, Gislason GH, Charlot M, Jorgensen CH, Lindhardsen J, Olesen JB, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270(2):147–57.CrossRefPubMedGoogle Scholar
  4. 4.
    Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009;68(7):1131–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Eder L, Chandran V, Cook R, Gladman DD. The risk of developing diabetes mellitus in patients with psoriatic arthritis: a cohort study. J Rheumatol. 2017;44(3):286–91.CrossRefPubMedGoogle Scholar
  6. 6.
    Love TJ, Zhu Y, Zhang Y, Wall-Burns L, Ogdie A, Gelfand JM, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis. 2012;71(8):1273–7.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    • Polachek A, Touma Z, Anderson M, Eder L. Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies. Arthritis Care Res (Hoboken). 2017;69(1):67–74. Quantifies increased cardiovascular risk in psoriatic disease patients. Google Scholar
  8. 8.
    Miller IM, Skaaby T, Ellervik C, Jemec GB. Quantifying cardiovascular disease risk factors in patients with psoriasis: a meta-analysis. Br J Dermatol. 2013;169(6):1180–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013;133(10):2340–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2013;72(2):211–6.CrossRefPubMedGoogle Scholar
  11. 11.
    • Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2(2):e000062. Meta-analysis assessing the risk of major CV events in psoriasis patients. Google Scholar
  12. 12.
    Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69(6):1014–24.CrossRefPubMedGoogle Scholar
  13. 13.
    Mehta NN, Yu Y, Pinnelas R, Krishnamoorthy P, Shin DB, Troxel AB, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775 e1–6.CrossRefGoogle Scholar
  14. 14.
    Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Chin YY, Yu HS, Li WC, Ko YC, Chen GS, Wu CS, et al. Arthritis as an important determinant for psoriatic patients to develop severe vascular events in Taiwan: a nation-wide study. J Eur Acad Dermatol Venereol. 2013;27(10):1262–8.PubMedGoogle Scholar
  16. 16.
    Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken). 2011;63(12):1729–35.CrossRefGoogle Scholar
  17. 17.
    Haque N, Lories RJ, de Vlam K. Comorbidities associated with psoriatic arthritis compared with non-psoriatic spondyloarthritis: a cross-sectional study. J Rheumatol. 2016;43(2):376–82.CrossRefPubMedGoogle Scholar
  18. 18.
    Labitigan M, Bahce-Altuntas A, Kremer JM, Reed G, Greenberg JD, Jordan N, et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(4):600–7.CrossRefGoogle Scholar
  19. 19.
    Mok CC, Ko GT, Ho LY, Yu KL, Chan PT, To CH. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res (Hoboken). 2011;63(2):195–202.CrossRefGoogle Scholar
  20. 20.
    • Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326–32. Large population-based study comparing the risk of cardiovascular event in rheumatoid arthritis, psoriasis and PsA. Google Scholar
  21. 21.
    Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33(11):2167–72.PubMedGoogle Scholar
  22. 22.
    Wu S, Li WQ, Han J, Sun Q, Qureshi AA. Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women. Arthritis Rheumatol. 2014;66(2):304–10.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. Rheumatology (Oxford). 2008;47(5):718–23.CrossRefGoogle Scholar
  24. 24.
    Sattar N, McInnes IB. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol. 2005;17(3):286–92.CrossRefPubMedGoogle Scholar
  25. 25.
    Johnsen SH, Mathiesen EB, Joakimsen O, Stensland E, Wilsgaard T, Lochen ML, et al. Carotid atherosclerosis is a stronger predictor of myocardial infarction in women than in men: a 6-year follow-up study of 6226 persons: the Tromso Study. Stroke. 2007;38(11):2873–80.CrossRefPubMedGoogle Scholar
  26. 26.
    Tam LS, Shang Q, Li EK, Tomlinson B, Chu TT, Li M, et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum. 2008;59(9):1322–31.CrossRefPubMedGoogle Scholar
  27. 27.
    Eder L, Zisman D, Barzilai M, Laor A, Rahat M, Rozenbaum M, et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol. 2008;35(5):877–82.PubMedGoogle Scholar
  28. 28.
    Eder L, Jayakar J, Shanmugarajah S, Thavaneswaran A, Pereira D, Chandran V, et al. The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. Ann Rheum Dis. 2013;72(5):715–20.CrossRefPubMedGoogle Scholar
  29. 29.
    •• Spence JD, Eliasziw M, DiCicco M, Hackam DG, Galil R, Lohmann T. Carotid plaque area: a tool for targeting and evaluating vascular preventive therapy. Stroke. 2002;33(12):2916–22. Description of the evidence related to the use of total plaque area as a surrogate outcome for clinical cardiovascular diseases. Google Scholar
  30. 30.
    Di Minno MN, Ambrosino P, Lupoli R, Di Minno A, Tasso M, Peluso R, et al. Cardiovascular risk markers in patients with psoriatic arthritis: a meta-analysis of literature studies. Ann Med. 2015;47(4):346–53.CrossRefPubMedGoogle Scholar
  31. 31.
    van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation. 2004;109(9):1089–94.CrossRefPubMedGoogle Scholar
  32. 32.
    Balci DD, Balci A, Karazincir S, Ucar E, Iyigun U, Yalcin F, et al. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol. 2009;23(1):1–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 2007;57(6):1074–80.CrossRefPubMedGoogle Scholar
  34. 34.
    Baldassarre D, Veglia F, Hamsten A, Humphries SE, Rauramaa R, de Faire U, et al. Progression of carotid intima-media thickness as predictor of vascular events: results from the IMPROVE study. Arterioscler Thromb Vasc Biol. 2013;33(9):2273–9.CrossRefPubMedGoogle Scholar
  35. 35.
    • Eder L, Thavaneswaran A, Chandran V, Cook R, Gladman DD. Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. Ann Rheum Dis. 2015;74(10):1830–5. The study found an association between the extent of inflammation related to psoriatic disaese and the burden of carotid atherosclerosis. Google Scholar
  36. 36.
    Voros S, Rinehart S, Qian Z, Joshi P, Vazquez G, Fischer C, et al. Coronary atherosclerosis imaging by coronary CT angiography: current status, correlation with intravascular interrogation and meta-analysis. JACC Cardiovasc Imaging. 2011;4(5):537–48.CrossRefPubMedGoogle Scholar
  37. 37.
    •• Shen J, Wong KT, Cheng IT, Shang Q, Li EK, Wong P, et al. Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease. Ann Rheum Dis. 2017;76(7):1237–44. The first study that used CT angio to investigate the burden of coronary atherosclerosis in psoriatic arthritis. The study found a high burden of atherosclerotic plaques compared to controls.Google Scholar
  38. 38.
    Mehta NN, Torigian DA, Gelfand JM, Saboury B, Alavi A. Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). J Vis Exp. 2012;63:e3777.Google Scholar
  39. 39.
    Tahara N, Kai H, Nakaura H, Mizoguchi M, Ishibashi M, Kaida H, et al. The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose-positron emission tomography. Eur Heart J. 2007;28(18):2243–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, et al. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med. 2009;50(10):1611–20.CrossRefPubMedGoogle Scholar
  41. 41.
    Abdelbaky A, Corsini E, Figueroa AL, Fontanez S, Subramanian S, Ferencik M, et al. Focal arterial inflammation precedes subsequent calcification in the same location: a longitudinal FDG-PET/CT study. Circ Cardiovasc Imaging. 2013;6(5):747–54.CrossRefPubMedGoogle Scholar
  42. 42.
    Rose S, Dave J, Millo C, Naik HB, Siegel EL, Mehta NN. Psoriatic arthritis and sacroiliitis are associated with increased vascular inflammation by 18-fluorodeoxyglucose positron emission tomography computed tomography: baseline report from the Psoriasis Atherosclerosis and Cardiometabolic Disease Initiative. Arthritis Res Ther. 2014;16(4):R161.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Naik HB, Natarajan B, Stansky E, Ahlman MA, Teague H, Salahuddin T, et al. Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET/CT and neutrophil activation in a prospective observational study. Arterioscler Thromb Vasc Biol. 2015;35(12):2667–76.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Mehta NN, Yu Y, Saboury B, Foroughi N, Krishnamoorthy P, Raper A, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol. 2011;147(9):1031–9.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Gisondi P, Fantin F, Del Giglio M, Valbusa F, Marino F, Zamboni M, et al. Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology. 2009;218(2):110–3.CrossRefPubMedGoogle Scholar
  46. 46.
    Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(13):1318–27.CrossRefPubMedGoogle Scholar
  47. 47.
    Sharma A, Reddy MH, Sharma K, Dogra S, Vijayvergiya R. Study of endothelial dysfunction in patients of psoriatic arthritis by flow mediated and nitroglycerine mediated dilatation of brachial artery. Int J Rheum Dis. 2016;19(3):300–4.CrossRefPubMedGoogle Scholar
  48. 48.
    Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther. 2005;7(3):R634–43.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Eder L, Gladman DD. Predictors for clinical outcome in psoriatic arthritis—what have we learned from cohort studies? Expert Rev Clin Immunol. 2014;10(6):763–70.CrossRefPubMedGoogle Scholar
  50. 50.
    Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331(7):417–24.CrossRefPubMedGoogle Scholar
  51. 51.
    Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, Pineiro A, Garcia-Porrua C, Miranda-Filloy JA, et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum. 2007;57(1):125–32.CrossRefPubMedGoogle Scholar
  52. 52.
    Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum. 2007;36(4):203–9.CrossRefPubMedGoogle Scholar
  53. 53.
    • Eder L, Wu Y, Chandran V, Cook R, Gladman DD. Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. Ann Rheum Dis. 2016;75(9):1680–6. A large longitudinal cohort study that found clinical predictors for clinical cardiovascular events in psoriatic arthritis.Google Scholar
  54. 54.
    Battistoni A, Rubattu S, Volpe M. Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. Int J Cardiol. 2012;157(2):160–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Pietrzak A, Bartosinska J, Blaszczyk R, Chodorowska G, Brzozowski W, Hercogova J, et al. Increased serum level of N-terminal pro-B-type natriuretic peptide as a possible biomarker of cardiovascular risk in psoriatic patients. J Eur Acad Dermatol Venereol. 2015;29(5):1010–4.CrossRefPubMedGoogle Scholar
  56. 56.
    Eder L, Jayakar J, Pollock R, Pellett F, Thavaneswaran A, Chandran V, et al. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis. 2013;72(12):1956–61.CrossRefPubMedGoogle Scholar
  57. 57.
    Li RC, Krishnamoorthy P, DerOhannessian S, Doveikis J, Wilcox M, Thomas P, et al. Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors. Clin Exp Dermatol. 2014;39(1):19–24.CrossRefPubMedGoogle Scholar
  58. 58.
    Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003;46(4):459–69.CrossRefPubMedGoogle Scholar
  59. 59.
    Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999;99(9):1141–6.CrossRefPubMedGoogle Scholar
  60. 60.
    Atzeni F, Sarzi-Puttini P, Sitia S, Tomasoni L, Gianturco L, Battellino M, et al. Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. J Rheumatol. 2011;38(8):1661–4.CrossRefPubMedGoogle Scholar
  61. 61.
    Gentile M, Peluso R, Di Minno MND, Costa L, Caso F, de Simone B, et al. Association between small dense LDL and sub-clinical atherosclerosis in patients with psoriatic arthritis. Clin Rheumatol. 2016;35(8):2023–9.CrossRefPubMedGoogle Scholar
  62. 62.
    Kristensen SL, McInnes IB, Sattar N. Psoriasis, psoriatic arthritis and cardiovascular risk: are we closer to a clinical recommendation? Ann Rheum Dis. 2015;74(2):321–2.CrossRefPubMedGoogle Scholar
  63. 63.
    Crowson CS, Gabriel SE. Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment. Ann Rheum Dis. 2011;70(5):719–21.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    • Mehta NN, Krishnamoorthy P, Yu Y, Khan O, Raper A, Van Voorhees A, et al. The impact of psoriasis on 10-year Framingham risk. J Am Acad Dermatol. 2012;67(4):796–8. The study illustrated the limitation of Framingham Risk Score in predicting clinical cardiovascular events in psoriasis. Google Scholar
  65. 65.
    Ernste FC, Sanchez-Menendez M, Wilton KM, Crowson CS, Matteson EL, Maradit KH. Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study. Arthritis Care Res (Hoboken). 2015;67(7):1015–21.CrossRefGoogle Scholar
  66. 66.
    Eder L, Chandran V, Gladman DD. The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann Rheum Dis. 2014;73(11):1990–6.CrossRefPubMedGoogle Scholar
  67. 67.
    Ibanez-Bosch R, Restrepo-Velez J, Medina-Malone M, Garrido-Courel L, Paniagua-Zudaire I, Loza-Cortina E. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients: a study based on carotid ultrasound. Rheumatol Int. 2017;37(1):107–12.CrossRefPubMedGoogle Scholar
  68. 68.
    Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med. 2012;19(4):403–88.CrossRefPubMedGoogle Scholar
  69. 69.
    •• Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17–28. The recent EULAR recommendations for the managemnt of cardiovascular disease in rheumatic patients. Google Scholar
  70. 70.
    Kimball AB, Szapary P, Mrowietz U, Reich K, Langley RG, You Y, et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;67(1):76–85.CrossRefPubMedGoogle Scholar
  71. 71.
    Rutter MK, Kane K, Lunt M, Cordingley L, Littlewood A, Young HS, et al. Primary care-based screening for cardiovascular risk factors in patients with psoriasis. Br J Dermatol. 2016;175(2):348–56.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Jafri K, Bartels CM, Shin D, Gelfand JM, Ogdie A. Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken). 2017;69(1):51–7.CrossRefGoogle Scholar
  73. 73.
    Parsi KK, Brezinski EA, Lin TC, Li CS, Armstrong AW. Are patients with psoriasis being screened for cardiovascular risk factors? A study of screening practices and awareness among primary care physicians and cardiologists. J Am Acad Dermatol. 2012;67(3):357–62.CrossRefPubMedGoogle Scholar
  74. 74.
    Menter A, Griffiths CE, Tebbey PW, Horn EJ, Sterry W, International Psoriasis C. Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. J Eur Acad Dermatol Venereol. 2010;24(12):1371–7.CrossRefPubMedGoogle Scholar
  75. 75.
    Ridker PM. Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates? Curr Atheroscler Rep. 2013;15(1):295.CrossRefPubMedGoogle Scholar
  76. 76.
    Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52(2):262–7.CrossRefPubMedGoogle Scholar
  77. 77.
    • Ahlehoff O, Skov L, Gislason G, Gniadecki R, Iversen L, Bryld LE, et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol. 2015;29(6):1128–34. Large population-based study using administrative data to assess the impact of biologic and non-biologic drugs for psoriasis on cardiovascular events. Google Scholar
  78. 78.
    Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernan MA, Ridker PM, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108(9):1362–70.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Jokai H, Szakonyi J, Kontar O, Marschalko M, Szalai K, Karpati S, et al. Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: results of a pilot study. J Am Acad Dermatol. 2013;69(4):523–9.CrossRefPubMedGoogle Scholar
  80. 80.
    Tam LS, Li EK, Shang Q, Tomlinson B, Li M, Leung YY, et al. Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study. Ann Rheum Dis. 2011;70(4):705–6.CrossRefPubMedGoogle Scholar
  81. 81.
    • Eder L, Joshi A, Chandran V, Dey A, Cook RJ, Chaturvedi A, et al. TNFα inhibitors are associated with reduced progression of carotid atherosclerotic plaques by ultrasound and an improvement in aortic arch vascular inflammation by 18-FDG PET/CT in psoriasis and psoriatic arthritis patients—a prospective study from two cohorts [abstract]. Arthritis Rheum. 2016;68(suppl 10). An observational study assessing the impact of TNF inhibition on atherosclerotic plaques and vascular inflammation. Google Scholar
  82. 82.
    Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244–50.CrossRefPubMedGoogle Scholar
  83. 83.
    Yang ZS, Lin NN, Li L, Li Y. The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis. Clin Rev Allergy Immunol. 2016;51(2):240–7.CrossRefPubMedGoogle Scholar
  84. 84.
    Ramonda R, Puato M, Punzi L, Rattazzi M, Zanon M, Balbi G, et al. Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study. Joint Bone Spine. 2014;81(5):421–5.CrossRefPubMedGoogle Scholar
  85. 85.
    Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, et al. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2013;27(10):1252–61.PubMedGoogle Scholar
  86. 86.
    Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2017;176(4):890–901.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Ridker PM. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Trans Am Clin Climatol Assoc. 2013;124:174–90.PubMedPubMedCentralGoogle Scholar
  88. 88.
    Eder L, Gladman DD. Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Ther Adv Musculoskelet Dis. 2015;7(5):187–95.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Faculty of MedicineUniversity of TorontoTorontoCanada
  2. 2.Division of RheumatologyWomen’s College HospitalTorontoCanada
  3. 3.Department of MedicineUniversity of TorontoTorontoCanada

Personalised recommendations